Form 4: Heartflow CEO Farquhar Reports Stock Transactions

Heartflow CEO John C.M. Farquhar reported recent transactions including RSU grants, option awards, and a sale of common stock.

Summary

• John C.M. Farquhar, CEO and Director of Heartflow, Inc., reported multiple transactions involving the company's common stock and derivative securities.
• On February 6, 2026, 1,541 shares of common stock were disposed of at $27.74 to satisfy income tax withholding obligations related to the vesting of previously reported restricted stock units (RSUs).
• On the same date, 183,850 restricted stock units (RSUs) were acquired, with a vesting commencement date of February 6, 2026. These RSUs will vest 1/16th on each quarterly anniversary of the vesting commencement date, subject to continued service.
• Also on February 6, 2026, 321,259 stock options were acquired with an exercise price of $27.74. These options vest 1/48th on each monthly anniversary of the vesting commencement date and expire on February 6, 2036.
• On February 10, 2026, 22,562 shares of common stock were sold at a weighted average price of $27.46. This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Farquhar on September 12, 2025.
• Following these transactions, Mr. Farquhar beneficially owns 591,656 shares of common stock directly and 321,259 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider disclosure. While a sale of shares occurred, it was pre-planned under a Rule 10b5-1 plan, and significant new equity grants align the CEO with long-term company performance.

Positives

• The CEO received a significant grant of 183,850 restricted stock units (RSUs) and 321,259 stock options, aligning his interests with long-term shareholder value through future vesting schedules.
• The vesting schedules for both RSUs (1/16th quarterly) and stock options (1/48th monthly) incentivize continued service and performance over several years.

Negatives

• The CEO sold 22,562 shares of common stock, which could be perceived as a reduction in direct ownership, although it was part of a pre-planned trading arrangement.

Future Outlook

The filing indicates future vesting of 183,850 restricted stock units (RSUs) on a quarterly basis, and 321,259 stock options on a monthly basis, both commencing from February 6, 2026, subject to continued service. The stock options have an expiration date of February 6, 2036.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for executives and directors of publicly traded companies, detailing changes in their beneficial ownership. These transactions, particularly those involving equity grants and pre-planned sales, are common mechanisms for executive compensation and personal financial management within the regulatory framework.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency into the CEO's direct ownership changes and compensation structure. The grants align the CEO's interests with long-term shareholder value, while the pre-planned sale provides liquidity for the executive.
• Employees: The vesting schedules for RSUs and options are tied to continued service, which can influence employee retention and motivation, particularly for key executives.

Next Steps

• Quarterly vesting of 1/16th of the 183,850 RSUs, commencing February 6, 2026.
• Monthly vesting of 1/48th of the 321,259 stock options, commencing February 6, 2026.

Key Dates

Recommendation

The transactions present a mixed signal: a pre-planned sale of shares by the CEO for liquidity purposes, offset by substantial new grants of restricted stock units and stock options. The grants demonstrate continued long-term alignment with company performance, while the sale, being pre-scheduled, does not necessarily indicate a change in management's outlook. Therefore, a 'hold' recommendation is appropriate as these transactions do not fundamentally alter the investment thesis.

Keywords

Heartflow, HTFL, Insider Trading, Form 4, SEC Filing, Stock Options, Restricted Stock Units, CEO Transactions, Rule 10b5-1 Plan